Lupin launches Mirabegron Extended-Release tablets

22 Apr 2024 Evaluate

Lupin has launched Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (USFDA).

Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc. Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of $1,019 million in the U.S. (IQVIA MAT February 2024).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2127.50 -20.10 (-0.94%)
28-Jan-2026 12:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1615.50
Dr. Reddys Lab 1225.00
Cipla 1318.60
Zydus Lifesciences 890.75
Lupin 2127.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×